• Video
    lock
    Manufacturing / B Roll
    NIBR Basel
  • Video
    lock
    Locations / B Roll
    Physic Garden 3, Novartis Campus
  • Video
    lock
    Locations / B Roll
    Square 3, Novartis Campus
  • Video
    lock
    Disease Awareness / Video
    Managing the TSC Transition to Adult Care

    Ann describes how to live with symptoms as an adult living with Tuberous Sclerosis Complex (TSC) .

  • Image
    lock
    Leadership / Image
    Rob Kowalski

    Chief People & Organization Officer of Novartis

  • PDF
    lock
    Products / Infographic
    Interleukin 17-A (IL-17A) in Psoriasis

    A cornerstone cytokine (messenger protein) involved in the development of psoriasis and other autoimmune diseases.

  • PDF
    lock
    Products / Infographic
    Interleukin 17-A (IL-17A) in Inflammatory Joint Disease

    IL-17A helps fight infection but in chronic inflammatory joint diseases, IL-17A is a key cytokine involved in disease development.

  • Image
    lock
    Products / Image
    Kymriah™ (tisagenlecleucel) suspension for intravenous infusion

    Photo of Kymriah™ (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019.

  • PDF
    lock
    Products / Fact Sheet
    RTH258 Brolucizumab Clinical Trials

    Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.

  • PDF
    lock
    Products / Fact Sheet
    Kymriah™(tisagenlecleucel) in children and young adults with B-cell ALL that is refractory or relapsed at least twice

    Kymriah (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US

  • PDF
    lock
    Products / Fact Sheet
    The JULIET Clinical Trial

    The JULIET clinical trial is a global, multi-center Phase II registration trial investigating CTL019 (tisagenlecleucel) for use in diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL). The Novartis-sponsored JULIET trial was conducted in collaboration with the University of Pennsylvania to evaluate the safety and efficacy of CTL019 in adult patients with relapsed or refractory (r/r) DLBCL. Relapsed/refractory DLBCL is an aggressive (fast-growing), complex and difficult-to-treat disease, and patients with DLBCL often have worse prognosis than other forms of NHL.

  • PDF
    lock
    Products / Fact Sheet
    How does ACZ885 work?

    ACZ885 is a human monoclonal antibody, which is a protein that is designed to bind to only one substance in the body. ACZ885 is designed to bind to human interleukin-1β (IL-1β).